ImmunityBio Presents ANKTIVA and BCG Treatment Comparison Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Should l Buy IBRX?
Source: Newsfilter
- Efficacy Comparison Analysis: ImmunityBio will present comparative results of ANKTIVA plus BCG against other therapies at the 2026 American Urological Association Annual Meeting, aiming to enhance treatment options for patients with BCG-unresponsive non-muscle invasive bladder cancer, thereby improving clinical decision-making effectiveness.
- Innovative Treatment Exploration: Research on recombinant BCG (rBCG) in BCG-naïve patients indicates potential for earlier line treatment, reflecting the company's ongoing efforts to address BCG supply constraints and expand treatment options for patients.
- Clinical Trial Updates: ImmunityBio is advancing a randomized controlled trial for BCG-naïve patients to evaluate the safety and efficacy of rBCG, which will provide clinicians with a more comprehensive treatment framework to improve patient outcomes.
- IL-15 Mechanism Discussion: Founder Dr. Soon-Shiong will discuss the role of IL-15 in urological oncology at the meeting, emphasizing its importance in activating T cells and NK cells, further driving research advancements in bladder and prostate cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.110
Low
5.00
Averages
7.33
High
9.00
Current: 8.110
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio's Immunotherapy Approved in Saudi Arabia
- Saudi FDA Approval: ImmunityBio's Quilt 3005 immunotherapy has received approval from the Saudi FDA, enhancing the company's reputation in the Middle East and providing strong support for its global expansion strategy.
- FDA Review Dynamics: Investors are closely monitoring the FDA's review of ImmunityBio's resubmitted BLA for Anktiva plus BCG, with data indicating that 58.2% of patients remained cancer-free after 12 months, which could significantly impact future market performance.
- Stock Price Volatility: Although IBRX shares slid over 1% in Monday trading, they surged 20% last week, reflecting ongoing market interest and potential confidence in the company's immunotherapy.
- Global Expansion Plans: ImmunityBio's launch of Anktiva in Saudi Arabia and partnerships with local biopharma firms signify its expansion in the Middle East and North Africa, further solidifying its competitive position in the global market.
See More
ImmunityBio Plans Expansion in Turkey Amid AI Manufacturing Advances
- Global Expansion Plans: Founder Patrick Soon-Shiong hinted at ImmunityBio's global expansion, particularly in Turkey, indicating an acceleration of its international commercialization strategy, despite a 5% decline in stock price to $8.11 on Monday.
- AI Manufacturing Robot Nears Completion: The company's AI-driven NK cell manufacturing robot, internally called “Leonardo,” is nearing completion and is expected to mass-produce natural killer cells, significantly enhancing ImmunityBio's production capabilities and competitive position in cancer immunotherapy.
- International Market Dynamics: Soon-Shiong's inspection of the manufacturing robot in Italy coincides with ImmunityBio securing approvals for its immunotherapy candidate Anktiva in multiple countries, showcasing the company's expansion momentum in the Middle East and North Africa, which boosts investor confidence in its international growth.
- Ongoing FDA Review: ImmunityBio's Anktiva is under FDA review for its supplemental biologics license application, with long-term data showing that 58.2% of patients remained cancer-free after 12 months, which could drive further development in the U.S. market.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding its immunotherapy Anktiva, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that promotional claims made in a podcast and TV ad about Anktiva were false or misleading, resulting in a more than 21% drop in the company's stock price that day, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging those who suffered significant losses during the class period to submit their losses for potential inclusion in the class action.
- Public Health Impact: The FDA warned that the pervasive misleading efficacy claims across various promotional materials could pose serious public health risks, as they grossly misrepresent the benefits of Anktiva, raising concerns about the company's accountability and transparency.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses once the truth was revealed to the market.
- Investor Rights Protection: The firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and seek compensation, noting that investors are not represented by an attorney until the class is certified.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email to ensure their rights are protected and to understand the steps to participate in the class action.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which reduces financial barriers and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true facts emerged, potentially impacting the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting misconduct within the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in the field.
See More
ImmunityBio's Immunotherapy Approved in Saudi Arabia
- Saudi FDA Approval: ImmunityBio's Quilt 3005 immunotherapy has received approval from the Saudi FDA, enhancing the company's reputation in the Middle East and providing strong support for its global expansion strategy.
- FDA Review Dynamics: Investors are closely monitoring the FDA's review of ImmunityBio's resubmitted BLA for Anktiva plus BCG, with data indicating that 58.2% of patients remained cancer-free after 12 months, which could significantly impact future market performance.
- Stock Price Volatility: Although IBRX shares slid over 1% in Monday trading, they surged 20% last week, reflecting ongoing market interest and potential confidence in the company's immunotherapy.
- Global Expansion Plans: ImmunityBio's launch of Anktiva in Saudi Arabia and partnerships with local biopharma firms signify its expansion in the Middle East and North Africa, further solidifying its competitive position in the global market.
See More
ImmunityBio Plans Expansion in Turkey Amid AI Manufacturing Advances
- Global Expansion Plans: Founder Patrick Soon-Shiong hinted at ImmunityBio's global expansion, particularly in Turkey, indicating an acceleration of its international commercialization strategy, despite a 5% decline in stock price to $8.11 on Monday.
- AI Manufacturing Robot Nears Completion: The company's AI-driven NK cell manufacturing robot, internally called “Leonardo,” is nearing completion and is expected to mass-produce natural killer cells, significantly enhancing ImmunityBio's production capabilities and competitive position in cancer immunotherapy.
- International Market Dynamics: Soon-Shiong's inspection of the manufacturing robot in Italy coincides with ImmunityBio securing approvals for its immunotherapy candidate Anktiva in multiple countries, showcasing the company's expansion momentum in the Middle East and North Africa, which boosts investor confidence in its international growth.
- Ongoing FDA Review: ImmunityBio's Anktiva is under FDA review for its supplemental biologics license application, with long-term data showing that 58.2% of patients remained cancer-free after 12 months, which could drive further development in the U.S. market.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading statements made by its Chief Scientific Officer regarding its immunotherapy Anktiva, with the class period spanning from January 19, 2026, to March 24, 2026, potentially impacting investors significantly.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that promotional claims made in a podcast and TV ad about Anktiva were false or misleading, resulting in a more than 21% drop in the company's stock price that day, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors and is urging those who suffered significant losses during the class period to submit their losses for potential inclusion in the class action.
- Public Health Impact: The FDA warned that the pervasive misleading efficacy claims across various promotional materials could pose serious public health risks, as they grossly misrepresent the benefits of Anktiva, raising concerns about the company's accountability and transparency.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses once the truth was revealed to the market.
- Investor Rights Protection: The firm encourages affected investors to contact them before May 26, 2026, to participate in the lawsuit and seek compensation, noting that investors are not represented by an attorney until the class is certified.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to reach out via phone or email to ensure their rights are protected and to understand the steps to participate in the class action.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notification: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which reduces financial barriers and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true facts emerged, potentially impacting the company's reputation and stock price.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, that they must apply to be lead plaintiff by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will not incur any upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that executives of ImmunityBio made false and misleading statements during the class period, resulting in investor losses when the true information was revealed, highlighting misconduct within the company.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having secured hundreds of millions in settlements, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and influence in the field.
See More
